Literature DB >> 20658636

Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation.

Hiroyuki Momota1, Yoshitaka Narita, Yoshitaka Nariata, Yasuji Miyakita, Ako Hosono, Atsushi Makimoto, Soichiro Shibui.   

Abstract

We present a case of a 12-year-old female with a germline TP53 mutation who presented with anaplastic astrocytoma and subsequent acute lymphoblastic leukemia (ALL) 13 months after starting treatment with temozolomide (TMZ). The patient had no family history of malignancy except her grand father and his siblings. Although alkylating agents such as TMZ are known to induce secondary hematologic malignancy, only several cases of treatment-related acute leukemia have been reported after TMZ-alone chemotherapy for malignant gliomas. We demonstrate a rare case of TMZ-related ALL in a child with glioma possibly associated with a germline TP53 mutation. 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20658636     DOI: 10.1002/pbc.22542

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  10 in total

Review 1.  Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.

Authors:  Christopher Wenzinger; Eli Williams; Alejandro A Gru
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

Review 2.  Therapy-related myeloid neoplasms: when genetics and environment collide.

Authors:  Megan E McNerney; Lucy A Godley; Michelle M Le Beau
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

3.  Temozolomide in relapsed pediatric brain tumors: 14 cases from a single center.

Authors:  Canan Akyüz; Haci Ahmet Demir; Ali Varan; Bilgehan Yalçin; Tezer Kutluk; Münevver Büyükpamukçu
Journal:  Childs Nerv Syst       Date:  2011-08-25       Impact factor: 1.475

4.  Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: A case report and review of the literature.

Authors:  Pengfei Liu; Peiwen Li; Ting Lei; Limei Qu; Haiyan Huang; Qingchun Mu
Journal:  Oncol Lett       Date:  2018-04-04       Impact factor: 2.967

5.  An early and rare second malignancy in a treated glioblastoma multiforme: is it radiation or temozolomide?

Authors:  Shina Goyal; Rabi Raja Singh; Sasidharan Balukrishna; Mandeep Bindra; Selvamani Backianathan
Journal:  J Clin Diagn Res       Date:  2015-04-01

6.  Configurational and Conformational Equilibria of N6-(2-Deoxy-d-erythro-pentofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-5- N-methylformamidopyrimidine (MeFapy-dG) Lesion in DNA.

Authors:  Stephanie N Bamberger; Chanchal K Malik; Markus W Voehler; Summer K Brown; Hope Pan; Tracy L Johnson-Salyard; Carmelo J Rizzo; Michael P Stone
Journal:  Chem Res Toxicol       Date:  2018-08-31       Impact factor: 3.739

7.  Secondary hematological malignancies associated with temozolomide in patients with glioma.

Authors:  Hiroyuki Momota; Yoshitaka Narita; Yasuji Miyakita; Soichiro Shibui
Journal:  Neuro Oncol       Date:  2013-03-21       Impact factor: 12.300

8.  Second cancers in patients with neuroendocrine tumors.

Authors:  Hui-Jen Tsai; Chun-Chieh Wu; Chia-Rung Tsai; Sheng-Fung Lin; Li-Tzong Chen; Jeffrey S Chang
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

9.  Characteristics of Li-Fraumeni Syndrome in Japan; A Review Study by the Special Committee of JSHT.

Authors:  Michinori Funato; Yukiko Tsunematsu; Fumito Yamazaki; Chieko Tamura; Tadashi Kumamoto; Masatoshi Takagi; Shunsuke Kato; Haruhiko Sugimura; Kazuo Tamura
Journal:  Cancer Sci       Date:  2021-05-01       Impact factor: 6.716

10.  Non-hodgkin lymphoma after treatment with extended dosing temozolomide and radiotherapy for a glioblastoma: a case report.

Authors:  Laura Van Ginderachter; Tony Cox; Ria Drijkoningen; Ruth Achten; Eric Joosens; Annelies Maes; Koen Theunissen; Jeroen Mebis
Journal:  Case Rep Oncol       Date:  2013-01-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.